Literature DB >> 24751449

Multi-dimensional indices to stage idiopathic pulmonary fibrosis: a systematic review.

Camilla Rozanski1, Marco Mura.   

Abstract

Idiopathic pulmonary fibrosis (IPF) has the highest mortality rate among all interstitial lung diseases, with a mean survival time of 2 to 3 years from the time of diagnosis. Prognosis is difficult to determine, due to the recognized heterogeneous progression of the disease, as well as lack of a well recognized staging system. This in turn raises challenges when considering therapeutic options for IPF patients, such as lung transplantation, versus a more conservative approach.  Multiple independent factors have been identified as prognostic indicators in IPF, and a number of studies have proposed multi-dimensional indices that combine several parameters in order to achieve a more accurate delineation of disease progression. In this systematic review, the Pubmed database was used to identify studies in the area of multi-dimensional staging of IPF.  We analysed and critically appraised previously proposed prognostic scoring systems. Our aim is to encourage research developments in this area to help identify an optimal multi-dimensional staging system for IPF.

Entities:  

Mesh:

Year:  2014        PMID: 24751449

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  6 in total

1.  Assessing the Therapeutic Response to Pirfenidone in Idiopathic Pulmonary Fibrosis: Can We Do Better than with Forced Vital Capacity Alone?

Authors:  Karishma Hosein; Jamie Le; Marco Mura
Journal:  Lung       Date:  2016-11-17       Impact factor: 2.584

2.  The CALIPER-Revised Version of the Composite Physiologic Index is a Better Predictor of Survival in IPF than the Original Version.

Authors:  Karishma S Hosein; Gianluigi Sergiacomi; Maurizio Zompatori; Marco Mura
Journal:  Lung       Date:  2019-12-02       Impact factor: 2.584

3.  A comparison of published multidimensional indices to predict outcome in idiopathic pulmonary fibrosis.

Authors:  Charles Sharp; Huzaifa I Adamali; Ann B Millar
Journal:  ERJ Open Res       Date:  2017-03-14

4.  Validation of the risk stratification score in idiopathic pulmonary fibrosis: study protocol of a prospective, multi-centre, observational, 3-year clinical trial.

Authors:  Gian Marco Manzetti; Karishma Hosein; Matthew J Cecchini; Keith Kwan; Mohamed Abdelrazek; Maurizio Zompatori; Paola Rogliani; Marco Mura
Journal:  BMC Pulm Med       Date:  2021-12-04       Impact factor: 3.317

5.  Predicting survival of patients with idiopathic pulmonary fibrosis using GAP score: a nationwide cohort study.

Authors:  Sang Hoon Lee; Song Yee Kim; Dong Soon Kim; Young Whan Kim; Man Pyo Chung; Soo Taek Uh; Choon Sik Park; Sung Hwan Jeong; Yong Bum Park; Hong Lyeol Lee; Jong Wook Shin; Eun Joo Lee; Jin Hwa Lee; Yangin Jegal; Hyun Kyung Lee; Yong Hyun Kim; Jin Woo Song; Sung Woo Park; Moo Suk Park
Journal:  Respir Res       Date:  2016-10-18

6.  Comparison of CPI and GAP models in patients with idiopathic pulmonary fibrosis: a nationwide cohort study.

Authors:  Sang Hoon Lee; Jong Sun Park; Song Yee Kim; Dong Soon Kim; Young Whan Kim; Man Pyo Chung; Soo Taek Uh; Choon Sik Park; Sung Woo Park; Sung Hwan Jeong; Yong Bum Park; Hong Lyeol Lee; Jong Wook Shin; Eun Joo Lee; Jin Hwa Lee; Yangin Jegal; Hyun Kyung Lee; Yong Hyun Kim; Jin Woo Song; Moo Suk Park
Journal:  Sci Rep       Date:  2018-03-19       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.